文献速递膀胱癌与上尿路尿路上皮癌

开放、机器人与腹腔镜根治性膀胱切除术(CORAL)随机试验的长期肿瘤学结局

Long-term Oncological Outcomes from an Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).
PubMed 文献 · Eur Urol · 2019-11-15

CORAL试验将60例肌层浸润性膀胱癌或高危非肌层浸润性膀胱癌患者随机分配至开放、机器人辅助或腹腔镜根治性膀胱切除术,分析5年肿瘤学结局。结果显示三组5年无复发生存率、癌症特异性生存率和总生存率均无显著差异,微创技术达到与开放手术相当的肿瘤学结局,但样本量小且为单中心。

要点

  • 三组5年RFS、CSS、OS均无显著差异
  • 微创技术与开放手术肿瘤学结局等效
  • 样本量小、单中心是主要局限

核心结论

  • 开放、机器人辅助和腹腔镜根治性膀胱切除术的5年无复发生存率、癌症特异性生存率和总生存率无显著差异。
  • 微创技术取得了与开放手术金标准相当的肿瘤学结局。

研究设计与样本

  • CORAL随机对照三臂试验,纳入60例肌层浸润性膀胱癌(n=38)或高危非肌层浸润性膀胱癌(n=21)患者,随机接受开放、机器人辅助或腹腔镜根治性膀胱切除术,并采用体外尿流改道。
  • 基于意向性治疗原则分析,采用Kaplan-Meier曲线和log-rank检验比较生存曲线,双侧p<0.05为显著。

主要发现

  • 开放、机器人辅助和腹腔镜组的5年无复发生存率分别为60%、58%和71%。
  • 开放、机器人辅助和腹腔镜组的5年癌症特异性生存率分别为64%、68%和69%。
  • 开放、机器人辅助和腹腔镜组的5年总生存率分别为55%、65%和61%。
  • 三组间无复发生存率、癌症特异性生存率和总生存率均无显著差异。

临床怎么用

  • 对于肌层浸润性膀胱癌或高危非肌层浸润性膀胱癌患者,微创根治性膀胱切除术可作为开放手术的等效选择。

局限性

  • 样本量小(共60例)。
  • 单中心研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The long-term oncological outcomes of laparoscopic (LRC) and robotic-assisted radical cystectomy (RARC) are still maturing compared with open radical cystectomy (ORC). OBJECTIVE: To evaluate the 5-yr oncological outcomes of patients recruited into the randomised trial of Open, Laparoscopic and Robot Assisted Cystectomy (CORAL) and extracorporeal urinary diversion. DESIGN, SETTING, AND PARTICIPANTS: A review of prospectively maintained database of 60 patients with muscle-invasive bladder cancer (MIBC) or high-risk nonmuscle-invasive bladder cancer (HRNMIBC) who were previously randomised in the CORAL trial to receive ORC, RARC, or LRC. This trial was designed to compare the perioperative and early oncological outcomes of these techniques. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcomes of interest included 5-yr recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS). Kaplan-Meier curves were used to plot the recurrence and survival data. The curves between RFS, CSS, and OS were compared using the log-rank test. A two-sided p value <0.05 was considered significant. Results were analysed on the basis of intention to treat. RESULTS AND LIMITATIONS: A total of 60 patients with either MIBC (n=38) or HRNMIBC (n=21) were randomised in the CORAL trial to receive ORC, RARC, or LRC. The 5-yr RFS was 60%, 58%, and 71%; 5-yr CSS was 64%, 68%, and 69%; and 5-yr OS was 55%, 65%, and 61% for ORC, RARC, and LRC, respectively. There was no significant difference in RFS, CSS, and OS between the three surgical arms. The principal limitation is the small sample size. CONCLUSIONS: There was no difference in 5-yr RFS, CSS, and OS rates of patients who underwent ORC, RARC, and LRC for management of bladder cancer. Minimally invasive techniques achieved equivalent oncological outcomes to the gold standard of ORC. However, the study was based at a single institution with a small sample size. PATIENT SUMMARY: Patients who agreed to participate in the randomised trial of either open, laparoscopic, or robotic-assisted radical cystectomy for bladder cancer did not have different cancer outcomes at 5yr.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Khan MS, Omar K, Ahmed K, et al. Long-term Oncological Outcomes from an Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL). Eur Urol. 2019. PMID: 31740072. doi:10.1016/j.eururo.2019.10.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。